The DOI matches its Crossref record.
Therapy Discovery for Pharmacoresistant Epilepsy and for Disease‐modifying Therapeutics: Summary of the NIH/NINDS/AES Models II Workshop
Abstract
The National Institutes of Health (NIH), through the Antiepileptic Screening Project (formerly known as the Antiepileptic Drug Development Program), has been a key element in the discovery and introduction of new pharmacologic therapies since the institution of the program more than 25 years ago. The program was established with the goals of facilitating the identification of new drugs that were safer and more efficacious epilepsy treatments. Through these efforts and leadership, the program has been highly successful, with the introduction of many new antiepileptic compounds, providing new and welcomed treatment options to epilepsy patients worldwide. In spite of these successes, these new drugs have yet to make a significant impact in the most difficult to treat conditions, or for those patients who are incompletely responsive to available pharmacologic treatments. It is estimated that more than one third of patients with epilepsy (∼750,000 Americans) belong in this pharmacoresistant category. Because of this large number of pharmacoresistant patients with epilepsy, a developing consensus mandates that the current process of therapy discovery and development must be reevaluated and enhanced in light of the evolution of available models and our understanding of epilepsy. Several large meetings (notably the White House–initiated conference, “Curing Epilepsy: Focus on the Future,” which was held in March 2000, and the NIH Workshop for Models for Epilepsy and Epileptogenesis, held in March 2001) started the process. One of the primary recommendations of these conferences was that the existing process of therapy discovery and development should be enhanced with a focus on developing preclinical models that would be more predictive of clinical success in stopping the seizures of patients currently incompletely controlled with existing therapies. In addition, strong recommendations were made to develop mechanisms to identify treatments that will prevent the development of epilepsy (epileptogenesis). A key element in this latter recommendation is the identification of appropriate models for epileptogenesis and the creation of a process that will use these models for antiepileptogenic therapy discovery. In response to these recommendations, a workshop was held in September 2002 to identify useful models for therapy discovery for treatment of resistant epilepsy and the actual prevention of the disease. The first goal of this conference focused on recommendations of models to identify potential new therapies and to predict the clinical efficacy of these therapies. The second was the development of a process that can be used to evaluate and add new and promising models as they come along. The following paragraphs are a summary of the meeting with an emphasis on the recommendations that were made regarding therapy resistance and epileptogenesis. Two working groups were created for the meeting: one to concentrate on issues of therapy-resistant epilepsy, and the other to focus on disease-modifying therapeutics (DzM). The two focus groups were asked to consider the potential of candidate models in predicting clinical success of any particular treatment. Other major considerations required in the evaluations were the relative ease of use and the potential parallels among the different human epilepsies. An important point of emphasis was that the evaluation and eventual recommendations must be focused on the potential for the models to be predictive for clinical success, not for the relative value of the models for basic epilepsy research, while acknowledging the critical need for the latter. This process of evaluation should at no time be considered a general ranking system of epilepsy models. The many models, in vitro and in vivo, possess important scientific value for our understanding of the mechanisms of epilepsy. Therefore the overall goal of this workshop was to apply these criteria toward model evaluation to identify the most scientifically feasible screening tools that might be currently applied for discovery of new therapies. The issues concerning animal models of and protocols for therapy resistance and disease modification are generally similar. Therefore the discussions during the breakout sessions focused on the most appropriate experimental approaches or protocols, in addition to the particular animal models themselves. Current therapy screening has been developed on the assumption that epilepsy treatments could be identified by using short-term induced seizures in normal brains. This approach has many advantages including the ready availability of the models and the ability to use these models in a serial screening process for multiple compounds. We wish to augment this approach to therapy screening by using animals that have abnormal brains and seizures. The animals or tissues used would have an increased propensity for seizures or recurrent spontaneous seizures. Although we believe this approach will prov
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Löscher, W. (2011) · Seizure · doi:10.1016/j.seizure.2011.01.003 · Cited by 932
Löscher, W., & Brandt, C. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003046 · Cited by 414
Mitochondrial dysfunction and oxidative stress: cause and consequence of epileptic seizures
Patel, M. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.08.021 · Cited by 392
Löscher, W. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2222-z · Cited by 367
Epileptogenesis in the dentate gyrus: a critical perspective
Dudek, F. E., & Sutula, T. P. (2007) · Progress in Brain Research · doi:10.1016/s0079-6123(07)63041-6 · Cited by 301
Self-citation
Metadata
- Authors
- Stables, J. P., Bertram, E., Dudek, F. E., Holmes, G., Mathern, G., Pitkanen, A., & White, H. S.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2003-11-25
- Volume
- 44
- Issue
- 12
- Pages
- 1472-1478
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2022637923
- Cited by
- 160
- References
- 0
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapy Discovery for Pharmacoresistant Epilepsy and for Disease‐modifying Therapeutics: Summary of the NIH/NINDS/AES Models II Workshop. https://app.cochat.ai/papers/10.1111/j.0013-9580.2003.32803.x
- The paper
- Stables, J. P., Bertram, E., Dudek, F. E., Holmes, G., Mathern, G., Pitkanen, A., & White, H. S. (2003). Therapy Discovery for Pharmacoresistant Epilepsy and for Disease‐modifying Therapeutics: Summary of the NIH/NINDS/AES Models II Workshop. Epilepsia. https://doi.org/10.1111/j.0013-9580.2003.32803.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.